The Philadelphia (Ph') chromosome is present in greater than 90% of patients with chronic myelogenous leukemia (CML) and in 2% t o 20% of those with acute leukemias, for which it is an important prognostic marker too. The chimeric BCR-ABL mRNAs resulting from the translocation encode either a 210-Kd or a 190-Kd protein. The techniques used t o detect Ph' chromosome include karyotyping, Southern analysis t o demonstrate bcr rearrangement, and polymerase chain reaction t o amplify the BCR-ABL transcripts. However, the routine performance of these methods by clinical laboratories is cumbersome, time consuming, and exposes laboratory personnel t o radioisotopes. We describe here the clinical application of a new method, the hybridization protection assay (HPA), which uses chemiluminescent acridinium-esterlabeled probes in conjunction with PCR for detection of the HE PHILADELPHIA (Ph') translocation [t(9;22) (q34; T qll)], a hallmark of chronic myelogenous leukemia (CML)'-* results from a break within a 5.8-kb region (the breakpoint cluster region or bcr) in the central part of the BCR gene on chromosome 2Z3 and leads to juxtapositioning of theABL oncogene (chromosome 9) with the BCR gene:,' The resulting hybrid BCR-ABL mRNA codes for a tumorspecific 210-Kd protein6 with enhanced tyrosine kinase enzymatic a~tivity.~,' At least two different species of this hybrid mRNA exist depending on whether exon 2 or exon 3 of bcr is spliced to exon 2 of the ABL gene, thereby giving rise to two closely related 210-Kd proteins? In contrast, in about half the cases of Ph'-positive acute leukemias, the Ph' chromosome, although cytogenetically indistinguishable from that in patients with CML, results from a breakpoint in the first intron of the BCR gene (proximal to the bcr)'0,1'2'2 and leads to the production of a truncated BCR-ABL transcript encoding a 190-Kd protein."'14 The Ph' chromosome is discernable in approximately 20% of adults with acute lymphoblastic leukemia (ALL)," 2% of adults with acute myeloblastic leukemia (AML), and 5% of children with ALL.'6 It is an important prognostic marker for both adult and pediatric ALL. Less than 30% of children with Phl-positive ALL are long-term survivors,'6 whereas 60% to amplified BCR-ABL sequences. The method is sensitive, specific, and can reliably distinguish between the transcripts for P190"R-ABL and P21OBCRpgL. In contrast t o the 2 days or longer required for conventional hybridization, HPA analysis can be completed in less than 30 minutes. We have successfully used this method t o analyze 60 leukemia samples (34 from Ph'-negative acute leukemias; 6 from Ph'-positive acute leukemias; and 20 from CML) with complete correlation (of BCR-ABL positivity or negativity) with the results of karyotype or Southern Blot analysis of genomic DNA for bcr rearrangement. Therefore, the HPA, in conjunction with PCR, appears t o provide a rapid and reliable test for the diagnosis of Ph'-positivity.
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Similarly, in adults with this disorder, the median remission duration is less than 1 year. Therefore, alternative treatment strategies have been advocated for patients with Phl-positive acute leukemias.I6 Hence, it is desirable to have a method that allows rapid and easy diagnosis of Ph' translocation, both in acute leukemia and CML. Amplification of the chimeric BCR-ABL transcripts by PCR has been used to diagnose Ph' positivity, to detect minimal residual disease in patients with CML, and to study the presence and significance of alternative splicing of BCR-ABL mRNA.I7 However, the technique, as currently used in most laboratories, is time consuming and requires radioisotopes. We describe here the clinical application of a hybridization technique involving acridinium-ester-labeled oligonucleotide probes that is sensitive, specific, and does not require the use of radioisotopes. This technique, in conjunction with PCR, allows same-day detection of BCR-ABL positivity from small amounts of peripheral blood.
MATERIALS AND METHODS
Patients. Blood samples were collected from patients with diagnosis of CML (chronic phase or blast crisis), or acute leukemia (both Ph'-positive and Ph'-negative). Informed consent was obtained from all patients before venesection.
Sample preparation and amplification. Total cellular RNA was extracted by previously described methods." RNA from K562 cells, an erythroid blast crisis cell line, and RNA from patient W, a Ph'-positive CML patient, were used as positive controls for mRNA containing bcr exon 3-ABL exon III9 and bcr exon 2-ABL exon I1 junctions: respectively. The ALL-1 cell line (kindly provided by Dr G. Rovera, Wistar Institute) was used as a positive control for the transcript encoding P19@CR-ABL." HL-60 (a promyelocytic leukemia cell line) and normal human endometrial RNA were used as negative controls. One microgram of total RNA from cell lines or Xoth of the total amount of RNA from 50 to 200 million white blood cells (WBCs) from patient samples was used for amplification reactions. The amplification method and the primers have been previously described." Amplification was performed for 40 cycles. 
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Because contamination has proven to be a significant problem in some laboratories using this exquisitely sensitive technique, we took the following precautions to ensure the accuracy of our results: (1) the thermal cycler was kept in a separate laboratory, away from the room where cell collection, RNA processing, and cDNA synthesis was performed; (2) no amplified samples were allowed to be brought back into the room where RNA processing was performed; (3) at least one negative control was run for each experiment; and (4) samples on each patient were run on at least two different occasions.
Hybridizationprotection assay (HPA). Acridinium-ester-labeled oligonucleotides complementary to the BCR-ABL junction sequences were synthesized by Gen-Probe, Inc (San Diego, CA). The basic methodology for preparation of these probes has been described previously?' The chemical labeling of the DNA probes with acridinium-ester was achieved by reacting alkylamine linkerarms, which were introduced during DNA synthesis, and an N-hydroxysuccinimide ester of a methyl acridinium phenyl ester. The bcr2-ABLII probe was a 28mer with 22 bases in bcr exon 2 and the bcr3-ABLII probe was a 25mer with 11 bases in bcr exon 3. These probes were used to detect transcripts encoding P2108CR.ABL. The BCRI-ABLII probe was a 26mer with 17 bases in BCRI and was used to detect transcripts coding for P190BCR-ABL. For hybridization, 10 pL of the amplified product was diluted to 50 pL in a 12 X 75-mm polypropylene tube. The sample was heated to 95°C for 3 minutes to denature the DNA and quick chilled on ice. To verify the results obtained by HPA, conventional Southern blotting and hybridization of all amplified samples was performed. Ten microliters of the amplified product was run on 3% Nusieve/l% Seakem (FMC, Rockland, ME) composite gels, transferred ovemight to Genescreen Plus membrane (New England, Nuclear, Boston, MA), and baked at 80°C for 2 hours. Oligonucleotide probes complementary to the junctional BCR-ABL sequence^'^ were 5' end-labeled with 32P and hybridization performed overnight using hybridization buffer with (for bcr3-ABLII and BCRI-ABLII) or without (for bcr2-ABLII probe) formamide. The membranes were washed as recommended by the manufacturer and exposed to Kodak XAR film (Eastman Kodak Co, Rochester, NY) for 3 to 48 hours. The bcr3-ABLII and bcr2-ABLII probes detect 200-bp and 125-bp long amplification products, respectively, while the BCRI-ABLII probe detects a 307-bp product.
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RESULTS
To determine the time of differential hydrolysis that will maximize the chemiluminescence from hybridized probe while reducing the signal from unhybridized probe to a minimum, hybridization reactions were performed in the presence or absence of the target. The hybridization mixtures were then incubated with the differential hydrolysis buffer at 60°C for various lengths of time and the residual chemiluminescence measured. The results of such an analysis for the bcr3-ABLII probe are presented in Fig 1. The half-life of the hybridized probe was approximately 9 minutes while that of the free probe was 19 seconds. Thus, the TIn of the hybridized probe compared with the free probe results in a differential hydrolysis ratio of 28. Similarly, the bcr2-ABLII and the BCRI-ABLII probes both demonstrated differential hydrolysis ratios of 30. Accordingly, a 6-minute differential hydrolysis step was chosen.
In our initial experiments we attempted to establish the sensitivity and specificity of the amplification process and detection of amplified products by HPA. These results are shown in Fig. 2 . Starting with 1 pg of total RNA from the K562 or the ALL-1 cells, serial 10-fold dilutions were performed with normal human endometrial RNA. After 40 cycles of amplification, the BCR-ABL message could be detected at a dilution of 1:106 and 1:104 with K562 and ALL-1 RNA, respectively. Because one-tenth of the final amplification product was used for analysis, this represents the equivalent of total RNA from "th of a cell and one cell, respectively (at 10 pgkell). The sensitivity of detection of chimeric transcripts with HPA was identical to that on Southern blots and there was no cross-reactivity between the probes detecting P190BcR-ABL and P210BCR-ABL. the resultsof HPA were consistent with those obtained with karyotypes and Southern blots. Interestingly, two acute leukemia patients who were positive by HPA were not known to be Ph'-positive because of inadequate metaphases on karyotyping at thc time of presentation. Subsequent cytogenetic evaluation at thc time of leukemic relapse in both these patients showed the presence of the Ph' chromosome. In addition, two CML patients who had a diploid karyotype but were positive by HPA were also found to have bcr rearrangement on Southern blots. All samples from Ph'-positive leukemias had HPA counts greater than 100,000 RLUs on HPA and could be clearly distinguished from samples from Phi-negative leukemias, which were usually less than 1,OOO RLUs. We have also used this technique successfully to dctcct minimal residual disease in individuals who are in complete cytogenetic remission following a-interferon therapy or allogeneic bone marrow transplantation (data not shown).
DISCUSSION
Rapid advances in our understanding of the molecular basis of human neoplasia have led to an increasing emphasis on the potential clinical applications of these discovcries. While the use of polymerase chain reaction (PCR) has increased the sensitivity of detection of the Ph' chromosome, confirmation of the amplified product has required Southern blotting, hybridization with radiolabeled probes, extensive washing, and, finally, autoradiography. As an alternative, HPA was investigated for the dctection of PCR-amplified product. HPA is an entirely homogeneous format that not only is nonradioactive, but also requires no physical separation of free versus hybridized probe. In the presence of the differential hydrolysis buffer, the rate of hydrolysis of free probe is much faster than that of the HPA in detecting PCR-amplfied produm from clinical specimens.
hybridized probe. As a consequence, separation Of hybridized probe from free probe on a solid Support iS UnnCCeSsary. Furthermore, elevated backgrounds traditionally associated with physical separation techniques are not a problcm with HPA.
yield and rapid chemiluminescent reaction kinetics. Alkyl-
Acridinium esters have high chcmilumin~scent quantum
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From amine linker-arms can be attached to synthetic DNA probes during DNA synthesis. The alkylamines are then used as labeling sites for acridinium esters. Such acridiniumester-labeled probes are fully compatible with solution hybridization methods. Solution hybridizations, as used by the HPA format, allow for faster kinetics relative to hybridizations performed on solid supports. Furthermore, with the ability to hydrolyze all free probe before detection with HPA, the amount of input probe can be adjusted to further drive the reaction kinetics. The amount of probe used and the time of hybridization for each of the probes was based on COTln determinations (data not shown).
Using the HPA format described in this report, the sensitivity of detection of chimeric BCR-ABL transcripts is equal to that with radiolabeled probes while the background signal from unhybridized probe is in the 0.002% to 0.005% range, thus allowing a clear distinction between the positive and negative samples. The probes used allow a differentiation between the transcripts encoding P190BcR-ABL and P210BCR-mL. Because this method is used in conjunction with PCR, it requires a much smaller sample than Southern blotting and, unlike cytogenetics, can be performed on peripheral blood. Furthermore, it can be successfully applied in instances where karyotyping is unsuccessful because of a lack of adequate metaphases. The rapidity of HPA allows the nonradioactive detection of the Phl translocation on the same day that the sample is obtained and, therefore, can help the physician make a more accurate assessment of prognosis before initiating therapy. Finally, our dilution experiments indicate one leukemic cell in a population of a million or more normal cells will give a positive result by this method, indicating that it may be used to detect minimal residual disease. It should be noted that the counts obtained by HPA may not increase linearly with the increase in the quantity of the starting template or the final amplification product. This result may be because of (1) nonlinearity inherent in the PCR system (due to varying efficiency of amplification depending on the amount of starting template); (2) the inability of the photomultiplier tube in the luminometer to discriminate individual chemiluminescent events above a certain signal-input level, especially signals greater than 100,000 RLUs; and (3) the competition between the opposite strand of the PCRamplified product and the probe for the probe target region during hybridization.
Besides its use for the detection of Phl-positive leukemias, HPA has potential for other clinical applications, too. Because of its ability to provide high stringency between closely related target sequences, the technique may be used to detect point mutations in cancer-related genes. Indeed, it has already been shown that one-or two-base mismatches in DNA from closely related bacteria such as meningococcus and gonococcus can be detected by HPA." Preliminary results suggest that it can also be exploited to discern point mutations in RAS protooncogenes.*I Finally, an increasing number of cytogenetic defects are being discovered in various tumors and, recently, other translocations encoding novel proteins have been cloned?2 This method should be easily applicable to the diagnosis and follow-up of these neoplasms.
